Elizabeth McMillan

Elizabeth McMillan has a diverse background in the pharmaceutical and research fields. Elizabeth is currently working as the Director of Integrative Cancer Biology at Odyssey Therapeutics since April 2022. Prior to this, they held various roles at Biosplice Therapeutics from November 2020 to April 2022, including Director of Target Discovery and Associate Director of Computational Biology. Before Biosplice Therapeutics, Elizabeth worked at Pfizer where they served as a Principal Scientist leading a team focused on generating and analyzing omics data within the Oncology R&D division from October 2019 to November 2020. Elizabeth also held the position of Senior Scientist at Pfizer from September 2018 to September 2019. Elizabeth began their career as a Postdoctoral Fellow at The Rockefeller University from July 2017 to July 2018.

Elizabeth McMillan earned their Bachelor's degree in Mathematics and Biology from New York University between 2007 and 2011. Elizabeth then pursued a Doctor of Philosophy (PhD) in Cell Biology, Computational and Systems Biology at UT Southwestern Medical Center. Elizabeth completed their PhD between 2011 and 2017.